Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options
|
|
- Sylvia Tucker
- 5 years ago
- Views:
Transcription
1 Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options September 19, 213 Boston, Massachusetts Educational Partner:
2 Session 3: Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options Learning Objectives 1. Evaluate the necessity of diagnostic testing in individual patients prior to diagnosis of IBS. 2. Choose appropriate nonpharmacologic or pharmacologic therapies to aid patients with IBS. 3. Manage the symptoms of IBS over the long term through effective treatment strategies. Faculty Lawrence R. Schiller, MD, FACS Professor of Internal Medicine Texas A&M Health Science Center, Dallas Campus Program Director Gastroenterology Fellowship Baylor University Medical Center Dallas, Texas Lawrence R. Schiller, MD, FACS, was born in Philadelphia, Pennsylvania, and attended Pennsylvania State University and Jefferson Medical College of Philadelphia. He completed his internal medicine training at Temple University Hospital in Philadelphia and then served in the US Army Medical Corps for 2 years. Dr Schiller moved to Texas in 1978 for training in gastroenterology at the University of Texas Southwestern Medical Center in Dallas and then stayed on the faculty at the medical school and was an attending physician at the Dallas VA hospital for 5 years. He moved to Baylor University Medical Center in Dallas in 1985 to continue research activities with John Fordtran, MD, and has been there ever since, most recently serving as program director for the gastroenterology fellowship. Dr Schiller has been involved with patient care as a founding partner of Digestive Health Associates of Texas, one of the largest singlespecialty gastroenterology practices in the United States, and has continued with research and education activities at Baylor University and University of Texas Southwestern. He is currently attending physician and chairman of the Institutional Review Board for Human Subject Protection at Baylor University as well as clinical professor of internal medicine at the University of Texas Southwestern, where he has won 2 fellow teaching awards. He has been elected to fellowships in the American College of Physicians and the American College of Gastroenterology (ACG) and has been governor for North Texas for the ACG. Dr Schiller currently is serving the ACG as president and has also served as president of the Texas Society for Gastroenterology and Endoscopy. Dr Schiller has published more than 8 papers and 45 book chapters dealing with gastric physiology, intestinal transport, diarrheal diseases, and motility disorders. Brian E. Lacy, MD, PhD Professor of Medicine Dartmouth Medical School Hanover, New Hampshire Director of the GI Motility Laboratory Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Brian E. Lacy, MD, PhD, is currently professor of medicine at the Geisel School of Medicine at Dartmouth, section chief of the division of gastroenterology & hepatology, and director of the GI Motility Laboratory at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr Lacy s clinical and basic science research interests focus on disorders of gastrointestinal motility, with an emphasis on irritable bowel syndrome, dyspepsia, gastroparesis, acid reflux disease, constipation, intestinal pseudo-obstruction, achalasia, and visceral pain. He is the author or coauthor of more than 85 peer-reviewed articles and the author or coauthor of numerous textbook chapters on gastrointestinal motility disorders and functional bowel disorders. Dr Lacy is a reviewer for a number of scientific journals and is a member of the American College of Gastroenterology, the American Gastroenterology Association, the American Motility Society, and the Rome Committee. Dr Lacy is the coauthor of a book for the general public on acid reflux disease, Healing Heartburn; is the author of Session 3
3 Making Sense of IBS, a book for the general public on irritable bowel syndrome; and is the editor and author of Curbside Consultations in IBS: 49 Clinical Questions. Dr Lacy earned his doctorate in cell biology from Georgetown University in Washington, DC, and his medical degree from the University of Maryland in Baltimore. Dr Lacy was a resident in internal medicine at the Dartmouth-Hitchcock Medical Center, where he continued his training as chief resident and then as a fellow in gastroenterology. He is board certified in gastroenterology. Faculty Financial Disclosure Statements The presenting faculty reports the following: Lawrence R. Schiller, MD, FACS, is a speaker for Ironwood Pharmaceuticals, Forest Laboratories, and Takeda Pharmaceuticals. He is a consultant for Synergy Pharmaceuticals. Brian E. Lacy, MD, PhD, serves on the scientific advisory board for Ironwood Pharmaceuticals, Forest Laboratories, and Takeda. Education Partner Financial Disclosure Statement The content collaborators at CME Incite report the following: Rose O Connor, PhD, and Monique Pond, PhD, have no financial relationships to disclose. Suggested Reading List Brandt LJ, Chey WD, Foxx-Orenstein AE, et al; for the American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 29;14(suppl 1):S1-S35. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 211;141(4): Cash BD, Chang E, Talley NJ, et al. Fresh perspectives in chronic constipation and other functional bowel disorders. Rev Gastroenterol Disord. 27;7(3): Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 212;35(5): Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 21;15(4): Chey WD, Lembo AJ, Lavins BJ, et al. Am J Gastroenterol. 212;17(11): Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 28;337:a2313. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN on the healthrelated quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 27;26(3): Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 28;336(7651): Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 23;349(14): Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 26;13(5): Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 212;17(11): Session 3
4 SESSION 3 11am 12:15pm Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options SPEAKERS Lawrence R. Schiller, MD, FACS Brian E. Lacy, MD, PhD Presenter Disclosure Information The following relationships exist related to this presentation: Lawrence R. Schiller, MD, FACS, is a speaker for Ironwood Pharmaceuticals, Forest Laboratories, and Takeda Pharmaceuticals. He is a consultant for Synergy Pharmaceuticals. Brian E. Lacy, MD, PhD, serves on the scientific advisory board for Ironwood Pharmaceuticals, Forest Laboratories, and Takeda. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Drug List Digesting the Facts in IBS: From Early Diagnosis to Effective Treatment Options Brian Lacy, MD, PhD Lawrence Schiller, MD Boston, Massachusetts September 19, 213 Lotronex Elavil, Tryptizol, Laroxyl, etc Celexa Norpramin, Pertofane Adapin, Silenor, Sinequan, etc Prozac, Sarafem, Fontex, etc Antideprin, Deprimin, Deprinol, etc Linzess Amitiza Colofac Paxil, Aropax, Seroxat, Pexeva, etc Xifaxan Alosetron Amitriptyline Citalopram Desipramine Doxepin Fluoxetine Imipramine Linaclotide Lubiprostone Mebeverine Paroxetine Rifaximin Learning Objectives Today s Agenda Evaluate the necessity of diagnostic testing in individual patients prior to diagnosis of irritable bowel syndrome (IBS) Choose appropriate nonpharmacologic or pharmacologic therapies to aid patients with IBS Manage the symptoms of IBS over the long term through effective treatment strategies Fact or Fiction? Select 1 for Fact Select 2 for Fiction Discussion of Case Study 1: Diane Discussion of Case Study 2: Mary Audience participation will enhance this program. 1
5 Rome III Criteria for IBS Positive IBS Diagnosis May Reduce Diagnostic Testing and Resource Utilization Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with 2 of the following: Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form of stool Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis Consider IBS a Diagnosis of Exclusion, % 8 IBS Experts (n=27) 72 Community Clinicians (n=281) Clinicians who believed IBS was a diagnosis of exclusion ordered 1.6 times more tests and spent $364 more on diagnostic tests per patient (P<.1) Longstreth GF, et al. Gastroenterology. 26;13: ; erratum in: Gastroenterology. 26;131:688. Spiegel BMR, et al. Am J Gastroenterol. 21;15: Alarm Features for IBS Yield of Colonoscopy in IBS Refractory or worsening abdominal symptoms Older patient ( 5 years; 45 years if African-American) Blood in stools Anemia Weight loss (unintentional) Anorexia Family history of organic gastrointestinal disease Lembo A, et al. N Engl J Med. 23;349: Brandt LJ, et al. Am J Gastroenterol. 25;1(suppl 1):S5-S21. Cash BD, et al. Rev Gastroenterol Disord. 27;7: If present, investigate and treat appropriately; colonoscopy may be indicated Histologic Findings in IBS Patients and Controls; Populations Not Matched for Age or Gender Lesion IBS Patients n=466 (%) Controls n=451 (%) P Value Adenomas 36 (7.7) 118 (26.1) <.1 Hyperplastic polyps 39 (8.4) 52 (11.5) NS Colorectal adenocarcinoma (.) 1 (.2) NS IBD 2 (.4) (.) NS Microscopic colitis 7 (1.5) N/A N/A Microscopic colitis was more common in a subset of patients with IBS-D who were 45 years (2.3%). IBD, inflammatory bowel disease; IBS-D, irritable bowel syndrome diarrhea-predominant; N/A, not applicable; NS, not significant. Chey WD, et al. Am J Gastroenterol. 21;15: Pretest Probability of Organic Disease 1 Organic Disease IBS Patients (%) Control/Population (%) Colitis/IBD Colorectal cancer (varies with age) Lactose malabsorption Thyroid dysfunction Celiac disease Celiac disease: antibodies Celiac disease: confirmed Bulking Agents for IBS-C: Systematic Review and Metaanalysis RCTs N Response* RR of Unimproved Symptoms NNT (95%CI) Fiber Placebo (95% CI) Overall % 43%.87 (.76-1.) 11 (5-1) Ispaghula % 36%.78 ( ) 6 (3-5) Bran % 46% 1.2 ( ) *Improved or resolved symptoms. Heterogeneity with ispaghula No evidence of publication bias 4 out of 5 bran studies of poor quality 1. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, et al. Am J Gastroenterol. 29;14(suppl 1):S1-S Cash BD, et al. Gastroenterology. 211;141: CI, confidence interval; NNT, number needed to treat; RCTs, randomized, controlled trials; RR, relative risk. Ford AC, et al. BMJ. 28;337:a
6 Responders Abdominal Discomfort (FDDQL), % Bifidobacterium animalis DN for IBS-C * 57 Week 3 Week 6 Probiotic (n=135) Placebo (n=132) Stool frequency increased in patients with <3 bowel movements/week *P=.3 Probiotic: fermented milk product (Activia ) containing B. animalis 1.25 x 1 1 CFU per serving, Streptococcus thermophilus, and Lactobacillus bulgaricus Patients With Improved Symptom Response, % Improvements in IBS Symptom Scores: Low FODMAP vs Control Diet * * Standard Diet Low FODMAP Diet *P.1 P<.5 CFU, colony forming unit; FDDQL, Functional Digestive Disorders QoL Questionnaire. Guyonnet D, et al. Aliment Pharmacol Ther. 27;26: Staudacher HM, et al. J Hum Nutr Diet. 211;24: What Are FODMAPs? Fermentable Oligo-, Di-, Monosaccharides And Polyols Antispasmodics for IBS Excess Fructose Fructans Sorbitol Raffinose Honey, apples, pears, peaches, mangos, fruit juice, dried fruit Wheat (large amounts), rye (large amounts), onions, leeks, zucchini Apricots, peaches, artificial sweeteners, artificially sweetened gums Lentils, cabbage, Brussels sprouts, asparagus, green beans, legumes 22 randomized controlled trials comparing 12 different antispasmodics vs placebo (N=1778 patients) Significant heterogeneity among studies Many agents not available in US Appear most useful for abdominal pain In meta-analysis, symptoms persist in 39% of patients receiving antispasmodics vs 56% of placebo-treated patients (RR:.68; 95% CI: ) Shepherd SJ, et al. J Am Diet Assoc. 26;16: Shepherd SJ, et al. Clin Gastroenterol Hepatol. 28;6: Gibson PR, et al. J Gastroenterol Hepatol. 21;25: Ford AC, et al. BMJ. 28;337:a2313. Global Relief of IBS Symptoms With TCAs/SSRIs TCAs: 9 studies (N=319 drug vs 256 control) Imipramine, desipramine, amitriptyline, doxepin*; doses 1-15 mg Meta-analysis favors treatment SSRIs: 5 studies (N=113 drug vs 117 control) Fluoxetine, paroxetine, citalopram*; dose 1-4 mg Meta-analysis favors treatment *These agents are not currently FDA approved for IBS. SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants. Ford AC, et al. Gut. 29;58: Psychological Therapies for IBS RR NNT Trials N 95% CI 95% CI Cognitive behavior therapy Relaxation training Dynamic psychotherapy Hypnotherapy Ford AC, et al. Gut. 29;58:
7 Alosetron: Therapeutic Gain for IBS-D Alosetron for IBS-D Study N Female, % Response: Alosetron, % Response: Placebo, % 1. Camilleri M, et al. Aliment Pharmacol Ther. 1999;13: Camilleri M, et al. Lancet. 2;355: Camilleri M, et al. Arch Intern Med. 21;161: Lembo T, et al. Am J Gastroenterol. 21;96: Jones R, et al. Aliment Pharmacol Ther. 1999;13: Therapeutic Gain, % Camilleri Camilleri Camilleri Lembo Jones 5 * *Comparison mebeverine instead of placebo. Mebeverine not available in the US. Female patients with chronic, severe IBS-D who failed other treatments Dose:.5-1. mg QD to BID Patient education regarding possible serious adverse effects of severe constipation or ischemic colitis.95 cases of ischemic colitis/1 patient-years.36 cases of severe constipation/1 patient-years If ischemic colitis occurs, it is usually within the first month of therapy Prescribing program mandated by FDA Requires patient to sign attestation form BID, twice a day; QD, once a day. Accessed May 15, 212. Rifaximin* Trials: Global Relief of IBS Without Constipation Rifaximin 2 Placebo T-I T-II Comb *Rifaximin is not currently FDA approved for IBS. Comb, Combination of both trials; T-I, TARGET 1 trial; T-II, TARGET 2 trial; TID, 3 times a day. Pimentel M, et al. N Engl J Med. 211;364: Adequate Symptom Relief, % 2 Phase 3 randomized controlled trials; N=126 patients Rifaximin 55 mg TID x 2 weeks; patients followed additional 1 weeks 4.7% vs 31.7% with adequate relief of global symptoms (P<.1) Rifaximin*: Most Extensively Studied Antibiotic for IBS Not systemically absorbed Doses studied for IBS: 4 mg BID to 55 mg TID Primary adverse effects include headache, abdominal pain, and upper respiratory tract infection *This agent is not currently FDA approved for IBS. Ford AC, et al. Clin Gastroenterol Hepatol. 29;7: Pimentel M, et al. N Engl J Med. 211;364: PEG for IBS-C # BMs Pain Level BMs, bowel movements; PEG, polyethylene glycol. Pretreatment Posttreatment 1. Brandt L, et al. Am J Gastroenterol. 29;14(suppl):S1-S Khoshoo V, et al. Aliment Pharmacol Ther. 26;23: No adult studies of laxatives in IBS-C 1 27 adolescents: PEG improved number of BMs (P<.5) but not pain in IBS-C patients 2 Mean SBM Frequency per Month Effect of Lubiprostone on IBS-C: Patients With Follow-up Over 52 Weeks Abdominal Pain/Discomfort Phase 3 Randomized Studies Withdrawal/Extension Studies Baseline Month of Treatment Month of Treatment P/L Group L/P/L Group L/L Group (n=179) (n=8) (n=261) N=52 IBS-C patients who completed 12 or 16 weeks of a placebo-controlled Phase 3 trial; patients enrolled in the extension study all received lubiprostone 8 µg BID SBM, spontaneous bowel movement. Chey WD, et al. Aliment Pharmacol Ther. 212;35: Change From Baseline 4
8 Mean Change From Baseline +/- SEM Efficacy of Linaclotide in Patients With IBS-C Treatment Period * N=8 BL Weeks Weeks Treatment Period Placebo Linaclotide 29 µg ANCOVA, analysis of covariance; RW, randomized withdrawal. Rao S, et al. Am J Gastroenterol. 212;17: RW Period z RW Treatment Sequence Placebo/linaclotide 29 µg Linaclotide 29 µg/linaclotide 29 µg Linaclotide 29 µg/placebo *P<.1 for linaclotide patients vs placebo patients (ANCOVA). P<.1 for linaclotide/linaclotide patients vs linaclotide/placebo patients (ANCOVA). Change in Worst Abdominal Pain, % Linaclotide Phase 3 IBS-C Trial: Abdominal Pain Over 26 Weeks BL ITT population, observed cases, LS-mean presented: P-values based on ANCOVA at each week. Bars represent 95% CI. ITT, intention to treat; LS, least squares. Chey WD, et al. Am J Gastroenterol. 212;17: Trial Week Linaclotide 29 µg P=.7 for week 1 P<.1 for weeks 2-26 Placebo N=84 Importance of Patient-Provider Relationship IBS patients who received placebo, augmented with empathetic HCP care reported significantly better outcomes than patients receiving placebo with limited HCP interactions Improvements in Global Adequate relief Symptom severity QoL 59% of IBS patients receiving only placebo and warm, empathetic care reported a decrease in symptom severity score at 6 weeks. Kaptchuk TJ, et al. BMJ. 28;336: QoL, quality of life. Partnering With Patients to Improve Treatment Adherence and Overall Outcomes Identify patients likely to have poor adherence 1 Provide clear instruction to simplify medication regimen 1 Listen and partner with patient to customize regimen 1 Reinforce desirable behaviors at follow-up visits 1 A good patient-physician relationship can improve adherence to treatment and patient satisfaction. 2,3 1. D Inca R, et al. Aliment Pharmacol Ther. 28;27: Osterberg L, et al. N Engl J Med. 25:353: Roter DL, et al. Doctors Talking With Patients/Patients Talking With Doctors: Improving Communication in Medical Visits. 26. INTRODUCING DIANE What should be our first course of action? 5
9 Which treatment would you recommend for Diane? How should we manage Diane s case over the long term? INTRODUCING MARY Was it necessary to perform these tests before diagnosing Mary with IBS? If Mary s diagnosis was IBS-C, which treatment would you offer her first? If Mary s diagnosis was IBS-D, which treatment would you offer her first? 6
10 Key Takeaways How should we manage Mary s case over the long term? Diagnose IBS in the absence of diagnostic test results in patients without alarm features Low-FODMAP diet, probiotics, psychological therapy all have clinical efficacy data in IBS Linaclotide and lubiprostone are FDA approved for IBS-C Alosetron is FDA approved for women with IBS-D Strategies to successfully manage symptoms of IBS over the long term include Regular assessment of IBS symptom response Adjustment of treatment strategy, if necessary Development of patient-physician partnership Aim to improve treatment adherence and patient satisfaction Question & Answer 7
What s the Latest? Rome III Criteria for IBS
Irritable Bowel lsyndrome: What s the Latest? American College of Gastroenterology Las Vegas, January 2014 Bi Brian E. Lacy, Ph.D., PhD M.D., MD FACG Professor of Medicine Geisel School of Medicine at
More informationRome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC
Rome III Criteria for IBS Irritable Bowel Syndrome: What s the Latest? Tim Burke, DO Pacific Digestive Associates Clackamas, OR Recurrent abdominal pain or discomfort at least 3 days/month in the last
More informationSESSION 5 2:30pm 3:45pm
SESSION 5 2:3pm 3:45pm Optimizing the Diagnosis, Treatment, and Management of Irritable Bowel Syndrome SPEAKERS Richard J. Saad, MD, MS Spencer Dorn, MD, MPH, MHA Presenter Disclosure Information The following
More informationManagement of Functional Bowel Disorders
Management of Functional Bowel Disorders Amy Foxx-Orenstein, DO, FACG, FACP Professor of Medicine Mayo Clinic Tucson Osteopathic Medical Foundation May 1, 2016 Objectives Review epidemiology and pathophysiology
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care May 1, 2013 Anaheim, California Educational Partner: Session 5: Under Pressure: The Need to Expedite IBS Diagnosis and Treatment
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care June 23, 2012 New York, New York Educational Partner: CME Incite, LLC Session 4: Under Pressure: The Need to Expedite IBS
More informationUnder Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care
Under Pressure: The Need to Expedite IBS Diagnosis and Treatment in Primary Care February 7, 2013 Fort Lauderdale, Florida Educational Partner: Session 4: Under Pressure: The Need to Expedite IBS Diagnosis
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationTreatment of IBS - Diet or Drugs?
Treatment of IBS - Diet or Drugs? Brooks D. Cash, MD, FACG Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Learning objectives Review the evolving
More informationState of the Art: Management of Irritable Bowel Syndrome
ACG/FGS Annual Spring Symposium March 16-18, 2018 Bonita Springs, FL State of the Art: Management of Irritable Bowel Syndrome William D. Chey, MD Professor of Medicine University of Michigan IBS: Rome
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationIBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner
Rome IV: Diagnostic Criteria* IBS: Updates on Diagnostics and Therapeutics for the Primary Practitioner Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director Northwestern Functional
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More informationRefractory IBS-D: An Evidence-Based Approach to Therapy
Refractory IBS-D: An Evidence-Based Approach to Therapy Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director, Northwestern Neurogastromotility, Functional, and Integrated Bowel
More information5 Things to Know About Irritable Bowel Syndrome
5 Things to Know About Irritable Bowel Syndrome Mike Kolber MD, CCFP, MSc PEIP 2017 Faculty/Presenter Disclosure Presenter: Mike Kolber Relationships that may introduce potential bias and/or conflict of
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationCurrent and Emerging Pharmacological Treatments in Irritable Bowel Syndrome
Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School What is the general
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationInflammatory or Irritable? (the bowel, not the speaker)
South GP CME Edgar Centre, Dunedin August 2014 Inflammatory or Irritable? (the bowel, not the speaker) Dr Jason Hill MBChB FRACP FRCP Edin Department of Gastroenterology, Southern DHB Dunedin School Of
More informationDisclosures. 4 th Annual Digestive Disease IBS: New Management Approaches. Early description of symptoms defining IBS 1849 W Cumming.
4 th Annual Digestive Disease IBS: New Management Approaches Disclosures Consultant Alkermes, Allergan, Forest, Ironwood, Prometheus, Salix Anthony Lembo, M.D. Beth Israel Deaconess Medical Center Harvard
More informationSlide #43. Disclosure of Financial Relationships. IBS: Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine
Disclosure of Financial Relationships : Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Anthony Lembo,
More informationIrritable Bowel Syndrome. Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016
Irritable Bowel Syndrome Paul Sheykhzadeh, DO, FACG Digestive Health Associates Reno, NV NAPNA Symposium March 5, 2016 Definition of Irritable Bowel Syndrome (IBS) Rome III Criteria Recurrent abdominal
More informationPresenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018
Presenter Irritable Bowel Syndrome Current evidence for diagnosis & management Julie Daniels DNP, CNM Assistant Professor Course Coordinator of Primary Care of Women Faculty at Frontier Nursing University
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationWilliam D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology
Dietary and Other Non-pharmacological Management of IBS William D. Chey, MD, FACG Nostrant Professor of Medicine Director GI Nutrition Program University of Michigan Peter Loftus, May 2, 2016 Page 1 of
More informationEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
Alimentary Pharmacology and Therapeutics Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation L. Chang*, W. D. Chey, D.
More informationWhat s New in IBS with Diarrhea. Dr. Geoffrey K. Turnbull, MD April 6, 2018.
What s New in IBS with Diarrhea Dr. Geoffrey K. Turnbull, MD April 6, 2018. Objectives To learn how to diagnose IBS with particular emphasis on patients who have diarrhea predominantly. Review management
More informationIrritable Bowel Syndrome: Current and Emerging Treatment Options
Irritable Bowel Syndrome: Current and Emerging Treatment Options Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD INTRODUCTION Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal
More informationPsycho-pharmacologic Therapy. Objectives
Psycho-pharmacologic Therapy for Functional Bowel Disorders John J. Hutchings, M.D. Assistant Professor of Medicine and Psychiatry Louisiana i State t University it School of Medicine i Department of Medicine
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Irritable bowel syndrome (IBS) has a variety of symptoms, most commonly cramping, abdominal pain, bloating, constipation, and diarrhea. Symptoms can vary from person to person,
More informationStatement of Sponsorship and Support
Case Studies in the Practical Evaluation and Management of Irritable Bowel Syndrome with Diarrhea Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationFood is Medicine: A Nutritional Approach to IBS and More. Kathleen N. Mueller, M.D. CAFP Scientific Symposium 2017
Food is Medicine: A Nutritional Approach to IBS and More Kathleen N. Mueller, M.D. CAFP Scientific Symposium 2017 Nutritional approaches to IBS:FODMaP. New insight into food influences and gout. Breast
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationThe long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome Dr Miranda Lomer RD Email: miranda.lomer@kcl.ac.uk What is IBS - ROME IV Criteria A functional bowel disorder in which
More informationAn Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome
An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome American College of Gastroenterology August 2014, Indianapolis Brian E. Lacy, Ph.D., M.D. Professor of Medicine, Geisel School
More information4) Irritable Bowel Syndrome - Dr. Shaikhani. Epidemiology. Pathophysiology. Burden. Diagnosis
4) Irritable Bowel Syndrome - Dr. Shaikhani Epidemiology A common disorder, with a 7% prevalence. Women are 1.5 times more likely to be affected than men, most commonly between ages 20-40 years. Onset
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationAn Evidence-based Approach to Irritable Bowel Syndrome. Robert Baldor, MD, FAAFP
An Evidence-based Approach to Irritable Bowel Syndrome Robert Baldor, MD, FAAFP Robert Baldor, MD, FAAFP Professor and Vice Chair, Department of Family Medicine and Community Health/Director, Community-Based
More informationIrritable Bowel Syndrome
68 TH ANNUAL MCGILL REFRESHER COURSE FOR FAMILY PHYSICIANS 2017 Irritable Bowel Syndrome Gad Friedman, MDCM, FRCPC Jewish General Hospital DISCLOSURES I have no disclosures LEARNING OBJECTIVES 1. Review
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationIRRITABLE BOWEL SYNDROME
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 IRRITABLE BOWEL SYNDROME DEFINITION: *FUNCTIONAL GASTROINTESTINAL DISORDER CHARACTERIZED
More informationTenapanor for irritable bowel syndrome with constipation
NIHR Innovation Observatory Evidence Briefing: February 2018 Tenapanor for irritable bowel syndrome with constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736 LAY SUMMARY Irritable bowel syndrome with constipation
More informationIrritable Bowel Syndrome 4/11/2017. New Insights in Irritable Bowel Syndrome. Overview
70 60 50 40 30 20 10 0 0 15 30 45 60 75 90 105 120 135 150 165 180 Time (Minutes) 4/11/2017 New Insights in Irritable Bowel Syndrome Christopher Chang, MD, PhD Division of Gastroenterology/Hepatology University
More informationFUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta
FUNCTIONAL DISORDERS TREATMENT ADVANCES Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta Name: Dr. Adriana Lazarescu Conflict of Interest Disclosure
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationIBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center
IBS Dan Carter, M.D. Institute of Gastroenterology Sheba medical center Epidemiology Irritable bowel syndrome is a common functional gastrointestinal disorder that manifests as abdominal pain or discomfort
More informationEvidence-based Treatment Strategies for
Evidence-based Treatment Strategies for Chronic Constipation William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria*: Chronic constipation Must include 2 of the following (>25%
More informationWilliam D Chey, 1 Anthony J Lembo, 2 James A Phillips, 3 David P Rosenbaum 4
Efficacy and safety of tenapanor in patients with constipationpredominant irritable bowel syndrome: a 12-week, double-blind, placebocontrolled, randomized phase 2b trial William D Chey, 1 Anthony J Lembo,
More informationIrritable bowel syndrome (IBS) is a chronic, potentially disabling
Evidence-Based Management of Irritable Bowel Syndrome With Diarrhea Mark Pimentel, MD Irritable bowel syndrome (IBS) is a chronic, potentially disabling disorder of the gastrointestinal (GI) tract with
More informationJointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals.
Accredited by Jointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals. Mark Pimentel, MD Cedars-Sinai Medical Center
More informationSession 3: The Fast Track: Improving the Management of Chronic Constipation and IBS-C in the Primary Care Setting
Session 3: The Fast Track: Improving the Management of Chronic Constipation and IBS-C in the Primary Care Setting Learning Objectives List the criteria for the diagnosis of chronic constipation and irritable
More informationChronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016
Chronic Abdominal Pain Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016 Disclosures Speaker Bureau for Allergan Pharmaceuticals Abdominal Pain - Definitions Acute occurring for several
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationIrritable Bowel Disease. Dr. Alexandra Ilnyckyj MD
Irritable Bowel Disease Dr. Alexandra Ilnyckyj MD Exactly what is IBS? Common condition affecting mostly women Symptoms are variable but they reflect altered gut movement (motility) and sensation Commonly
More informationIBS current status Peter Laszlo Lakatos
IBS current status Peter Laszlo Lakatos Semmelweis University 1st Department of Medicine Functional gastrointestinal disorders Chronic or fluctuating functional gastrointestinal symptoms that can not be
More informationWhat is Irritable Bowel Syndrome (IBS)?
What is Irritable Bowel Syndrome (IBS)? Irritable bowel syndrome (IBS) is a health issue found in your intestines (gut). IBS can cause symptoms such as: Belly pain. Cramping. Gas. Bloating (or swelling)
More informationLow FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015
Low FODMAP Dietary Approach For FGD/IBS Our Experience Charlotte McCamphill 19 th February 2015 CONTENTS What Is IBS What are FODMAPs Service Provision Audit Results Future Work WHAT IS IBS The Rome III
More informationDr. Melvyn Letier Constantiaberg Mediclinic October 2016
Dr. Melvyn Letier Constantiaberg Mediclinic October 2016 This presentation will enable you to: Understand the pathophysiology of IBS Recognize the clinical manifestations of IBS Make a confident diagnosis
More informationAddendum to NICE guideline CG61, Irritable bowel syndrome in adults
National Institute for Health and Care Excellence Draft for consultation Addendum to NICE guideline CG61, Irritable bowel syndrome in adults Diagnosis and management of irritable bowel syndrome in primary
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More informationDisclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016
Disclosures Beating the Bowel Blues: An Update on the Treatment of Irritable Bowel Syndrome Matthew Nelson, PharmDBCPS, Roosevelt University College of Pharmacy Matthew Nelson declares no conflicts of
More informationDiagnosis and Treatment of Irritable Bowel Syndrome
Special Issue Diagnosis and Treatment of Irritable Bowel Syndrome Myung Gyu Choi, M.D. Department of Internal Medicine The Catholic University of Korea, College of Medicine Kangnam St. Mary's Hospital
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationIrritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center
Ti tl e s l i d e - p a rt 1 Irritable Bowel Syndrome and Chronic Constipation Susan Lucak, M.D. Columbia University Medical Center Treatment of IBS Abdominal pain / discomfort Antispasmodics Antidepressants
More informationอภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น
อภ ชาต แสงจ นทร ภาคว ชาอาย รศาสตร คณะแพทย ศาสตร มหาว ทยาล ยขอนแก น Functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habits in the absence of detectable structural
More informationWhat Is the Low-FODMAP Diet?
LOW-FODMAP DIET What Is the Low-FODMAP Diet? FODMAP refers to a group of five sugars found in certain foods. These sugars are lactose, fructose (in excess), fructans, galactans and polyols. Specifically,
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationEvolving Therapy in Irritable Bowel Syndrome (IBS)
Evolving Therapy in Irritable Bowel Syndrome (IBS) Dr. Syed Mohammad Arif MBBS, FCPS (Medicine), MD (Gastro) Associate Professor Department of Medicine Dhaka Medical College A good set of bowels is worth
More informationManagement of the Refractory Functional GI Patient
Management of the Refractory Functional GI Patient Shanti Eswaran, MD Clinical Assistant Professor Division of Gastroenterology University of Michigan Ann Arbor, MI, USA Functional Bowel Disease A good
More informationIrritated by the Irritable Bowel Syndrome Does Anything Work?
Irritated by the Irritable Bowel Syndrome Does Anything Work? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationIrritable Bowel Syndrome. Kimberly Persley, MD Texas Digestive Disease Consultants NPPA Course 2015
Irritable Bowel Syndrome Kimberly Persley, MD Texas Digestive Disease Consultants NPPA Course 2015 Irritable Bowel Syndrome Bowels Patients NP/PA Irritable Employers Family Physicians Irritable Bowel Syndrome
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationUnderstanding and Managing IBS and CIC in the Primary Care Setting
May 2018 Volume 14, Issue 5, Supplement 3 Understanding and Managing IBS and CIC in the Primary Care Setting Brooks D. Cash, MD Chief of the Division of Gastroenterology, Hepatology, and Nutrition University
More informationIrritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) Dr Rex J Polson 17 th January 2018 Overview Description of the condition Discussion of symptoms and investigations that may be required Discussion of management and treatment
More informationNew Insights into Functional Bowel Disorders. Diagnostic and Non medical Treatment Challenges in IBS
Presenter Disclosure Information 1:45 2:45pm New Insights into Functional Bowel Disorders The following relationships exist related to this presentation: William Chey, MD, AGAF, FACG, FACP, is a consultant
More information10/1/2016. Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD. Kimberly Kearns, APN. Mary Davitt, PMHNP.
Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD Kimberly Kearns, APN Speakers Bureau: Medtronic Salix Pharmaceuticals Takeda Pharmaceuticals Mary Davitt, PMHNP None Rachel
More informationDelfini Group, LLC Evidence & Value based Solutions For Health Care Clinical Improvement Consults, Content, Seminars, Training & Tools
Delfini Group, LLC Evidence & Value based Solutions For Health Care Clinical Improvement Consults, Content, Seminars, Training & Tools Explicit Evidence based Clinical Practice Guideline Resource Information
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationIrritable bowel syndrome: An overview of diagnosis and pharmacologic treatment
REVIEW KEVIN W. OLDEN, MD Associate Professor of Medicine, Division of Gastroenterology, Mayo Clinic Scottsdale, Scottsdale, Ariz. Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationEfficacy of Linaclotide for Patients With Chronic Constipation
GASTROENTEROLOGY 2010;138:886 895 Efficacy of Linaclotide for Patients With Chronic Constipation ANTHONY J. LEMBO,* CAROLINE B. KURTZ, JAMES E. MACDOUGALL, B. J. LAVINS, MARK G. CURRIE, DONALD A. FITCH,
More information4 mg QHS; 3 wks RCT double-blind Global Improvement:
Web supplement Table 1. Placebo-Controlled Trials of IBS s Loperamide 7 N=60; males and 4 mg QHS; 3 wks Global Improvement: Abdominal Pain: Significant decrease in days with colicky pain in subgroup of
More informationIntestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response
Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response Blanca Serrano, 1 Silvia Delgado-Aros, 2 Fermín Mearin, 3 Constanza
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationObjectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose
Joshua D Noe, MD Associate Professor of Pediatric Gastroenterology Hepatology and Nutrition Medical College of Wisconsin I have no conflicts of interest to disclose Objectives Differentiate functional
More informationIrritable Bowel Syndrome and Chronic Constipation
Title slide - part 1 Irritable Bowel Syndrome and Chronic Constipation IBS - Physiologic Research Stress affects GI function Meals Pain / motility Time Line of Physiologic Research in IBS Pain sensitivit
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationWHOLE HEALTH: INFORMATION FOR VETERANS. Eating to Reduce Irritable Bowel Symptoms: The FODMaP Diet
WHOLE HEALTH: INFORMATION FOR VETERANS Eating to Reduce Irritable Bowel Symptoms: The FODMaP Diet Whole Health is an approach to health care that empowers and enables YOU to take charge of your health
More informationNEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A SEGUITO DELL ATTUAZIONE DELL ACCORDO STATO-REGIONI DEL 5/11/09 E SUCCESSIVE
NOME E NUMERO DEL PROVIDER: I&C SRL - 5387 ECM N : 180726 TITOLO: XVII CONGRESSO NAZIONALE GISMAD SEDE: MILANO, HOTEL NHOW DATA: 09-10/03/2017 NEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A
More informationThe treatment of irritable bowel syndrome
Therapeutic Advances in Gastroenterology Review The treatment of irritable bowel syndrome Brian E. Lacy, Kirsten Weiser and Ryan De Lee Abstract: Irritable bowel syndrome (IBS) is a highly prevalent functional
More informationIRRITABLE BOWEL SYNDROME
IRRITABLE BOWEL SYNDROME CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Here are some questions to ask your doctor. WHAT IS IRRITABLE BOWEL SYNDROME? 4
More informationDo Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief
More informationI. Identification Presenters: Date: Name of Organization: Goal Statement: Title of Presentation: Audience Description: Physical Set-up: -
I. Identification Presenters: Written by Jen Barnes, training will be presented by Cooking Matters managers Date: TBD Name of Organization: Cooking Matters Spring 2013 Contact: Jessica Caouette jcaouette@strength.org
More information